For patients with estrogen receptor positive (ER pos), human epidermal growth factor receptor 2 negative (HER2 neg) breast cancer the most challenging diagnostic decision is the separation of patients with low recurrence risk, who would benefit from endocrine therapy (ET) alone from those with high recurrence risk, who benefit from addition of chemotherapy (CTx) to ET. The gene discussed is ERBB2; the disease is breast cancer.